Patients, disease, and transplantation characteristics
Characteristics . | n = 107 . |
---|---|
Recipient | |
Median age, y (range) | 35 (3-56) |
Median weight, kg (range) | 65 (15-126) |
Male (%) | 67 (63) |
Children, 15 y or younger (%) | 17 (16) |
Positive CMV serology (%) | 46 (43) |
Underlying diagnosis | |
Chronic leukemia (%) | 68 (64) |
Acute leukemia (%) | 39 (36) |
Disease stage | |
Early (%) | 82 (77) |
Intermediate (%) | 20 (19) |
Advanced (%) | 5 (5) |
Donor | |
Median age, y (range) | 34 (2-65) |
Male (%) | 56 (52) |
Female donor to male recipient (%) | 31 (29) |
Sex match (%) | 56 (52) |
ABO match (%) | 72 (67) |
ABO major incompatibility (%) | 17 (16) |
Positive CMV serology (%) | 56 (55) |
Transplantation | |
Conditioning | |
TBI + CY ± others (%) | 32 (30) |
Bu + CY (%) | 58 (54) |
GVHD prophylaxis | |
CSA + MTX (%) | 94 (88) |
CSA + MTX + other (%) | 6 (6) |
CSA ± corticosteroids (%) | 7 (6) |
Graft composition | |
Median NC, 108/kg (range) | 2.4 (0.2-8.1) |
Median CD34, 106/kg (range) n = 83 | 3.6 (0.07-17.9) |
Characteristics . | n = 107 . |
---|---|
Recipient | |
Median age, y (range) | 35 (3-56) |
Median weight, kg (range) | 65 (15-126) |
Male (%) | 67 (63) |
Children, 15 y or younger (%) | 17 (16) |
Positive CMV serology (%) | 46 (43) |
Underlying diagnosis | |
Chronic leukemia (%) | 68 (64) |
Acute leukemia (%) | 39 (36) |
Disease stage | |
Early (%) | 82 (77) |
Intermediate (%) | 20 (19) |
Advanced (%) | 5 (5) |
Donor | |
Median age, y (range) | 34 (2-65) |
Male (%) | 56 (52) |
Female donor to male recipient (%) | 31 (29) |
Sex match (%) | 56 (52) |
ABO match (%) | 72 (67) |
ABO major incompatibility (%) | 17 (16) |
Positive CMV serology (%) | 56 (55) |
Transplantation | |
Conditioning | |
TBI + CY ± others (%) | 32 (30) |
Bu + CY (%) | 58 (54) |
GVHD prophylaxis | |
CSA + MTX (%) | 94 (88) |
CSA + MTX + other (%) | 6 (6) |
CSA ± corticosteroids (%) | 7 (6) |
Graft composition | |
Median NC, 108/kg (range) | 2.4 (0.2-8.1) |
Median CD34, 106/kg (range) n = 83 | 3.6 (0.07-17.9) |
Disease stage is based on International Bone Marrow Transplant Registry classification.
NC indicates nucleated cells.